---
title: "Genmab says Q2 2026 DARZALEX net sales total USD 4.21 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292750602.md"
description: "Genmab reported that Q2 2026 worldwide net trade sales of DARZALEX totaled USD 4.21 billion, as reported by Johnson & Johnson. U.S. net trade sales reached USD 2.44 billion, while rest-of-world sales totaled USD 1.77 billion. No percentage changes were disclosed in the update."
datetime: "2026-07-15T10:27:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292750602.md)
  - [en](https://longbridge.com/en/news/292750602.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292750602.md)
---

# Genmab says Q2 2026 DARZALEX net sales total USD 4.21 billion

-   Genmab reported Q2 2026 worldwide net trade sales of DARZALEX at USD 4.21 billion, as reported by Johnson & Johnson. \* U.S. net trade sales reached USD 2.44 billion; rest-of-world sales totaled USD 1.77 billion. \* No percentage changes were disclosed in the update. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [Genmab Updates Articles of Association, Expands Capital-Raising Flexibility](https://longbridge.com/en/news/295678408.md)
- [Capital Increase in Genmab as a Result of Employee Warrant Exercise](https://longbridge.com/en/news/295566458.md)
- [Weekly Recap: Epcoritamab‑lenalidomide PFS success and 2026 royalties rise](https://longbridge.com/en/news/295360680.md)
- [Genmab H1 FY26 operating profit rises 1% to USD 555 million; revenue increases 25% to USD 2.05 billion](https://longbridge.com/en/news/295122919.md)
- [Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)](https://longbridge.com/en/news/295329030.md)